You are here: Industry Insights > atezolizumab

News List

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors prnasia
December 06, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first two patients...
TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China prnasia
May 27, 2021
TransThera Biosciences Co. Ltd. announced that it has entered into a collaboration agreement with Roche to explore the combination of TT-00420 and atezolizumab for the treatment of patients in China with gastrointestinal ("GI") tract cancers.
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 prnasia
May 20, 2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with ...
Affimed, Roche Explore AFM24, Tecentriq Combo contractpharma
February 04, 2021
Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
FDA Announces Efficacy, Safety Concerns with Breast Cancer Treatment americanpharmaceuticalreview
September 14, 2020
The U.S. Food and Drug Administration (FDA) is alerting health care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab (Tecentriq) and paclitaxel in patients with previously untreated ...
Exelixis initiates phase 3 trial of Cabozantinib/Atezolizumab combo in prostate cancer pharmaceutical-business-review
July 06, 2020
Exelixis, Inc. announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been ...
FDA Approves Atezolizumab, plus Bevacizumab for Unresectable Hepatocellular Carcinoma americanpharmaceuticalreview
June 11, 2020
The Food and Drug Administration (FDA) has approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
BMI, Survival Linked in NSCLC Treated With Atezolizumab drugs
December 30, 2019
Baseline high body mass index (BMI) is associated with improved survival in patients with non-small cell lung cancer (NSCLC) treated with atezolizumab ...
FDA Approves atezolizumab with nab-paclitaxel, Carboplatin for Metastatic NSCLC americanpharmaceuticalreview
December 09, 2019
The Food and Drug Administration (FDA) has approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with paclitaxel protein-bound and ...
FDA OKs Tecentriq for Extensive-Stage Small Cell Lung Cancer drugs
March 20, 2019
Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer.

Previous page 1 2 Next page